Biology – E JEMED http://e-jemed.org/ Sat, 08 Jan 2022 11:26:44 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://e-jemed.org/wp-content/uploads/2021/05/default1-150x150.png Biology – E JEMED http://e-jemed.org/ 32 32 Biologists warn of aggressive moose after unusually deep December snow in interior Alaska https://e-jemed.org/biologists-warn-of-aggressive-moose-after-unusually-deep-december-snow-in-interior-alaska/ Sat, 08 Jan 2022 06:58:14 +0000 https://e-jemed.org/biologists-warn-of-aggressive-moose-after-unusually-deep-december-snow-in-interior-alaska/ A moose grazes along a road. (Emily Mesner / DNA) FAIRBANKS – It’s not just people who are a little irritated by the heavy snow this winter in the interior of Alaska. A wildlife official told Fairbanks TV station KTVF-TV that heavy snowfall and strong winds caused moose to act more aggressively towards humans. “The […]]]>

FAIRBANKS – It’s not just people who are a little irritated by the heavy snow this winter in the interior of Alaska.

A wildlife official told Fairbanks TV station KTVF-TV that heavy snowfall and strong winds caused moose to act more aggressively towards humans.

“The snowfall in December was really heavy,” said Tony Hollis, Fairbanks area wildlife biologist for the Department of Fisheries and Game. “This thick snow caused the moose not to want to stay in the snow. They want to be on the sidewalks, on the beaten track, or on groomed trails where commuting is easier for them.

Moose don’t want to be pushed off snow-cleared areas like streets and highways.

“They don’t want to have to travel in deep snow, and so if they are forced to, they get aggressive to stay on hard ground,” Hollis said.

Moose are also more aggressive when approaching people’s homes or properties, which adds concern to residents.

He advised people to be patient and wait for a moose to leave an area instead of trying to engage the moose, but says it can take a while because moose don’t move quickly. at this stage.

He said moose could get aggressive if people tried to fog them.

“They can be really stubborn, especially when they’re stressed like right now, and their response is to be aggressive when they’re stressed,” Hollis said. “Trying to suffocate a moose, push it, can make that animal aggressive, charge and attack.”


Source link

]]>
Development History of Global Alfalfa Concentrate Market 2021 Created by Top Manufacturer – Desialis, Shaanxi Jiaherb Phytochem, Naturalin, Nanjing Zhi Bai Cui Biology Technology https://e-jemed.org/development-history-of-global-alfalfa-concentrate-market-2021-created-by-top-manufacturer-desialis-shaanxi-jiaherb-phytochem-naturalin-nanjing-zhi-bai-cui-biology-technology/ Thu, 06 Jan 2022 11:36:17 +0000 https://e-jemed.org/development-history-of-global-alfalfa-concentrate-market-2021-created-by-top-manufacturer-desialis-shaanxi-jiaherb-phytochem-naturalin-nanjing-zhi-bai-cui-biology-technology/ the Global Alfalfa Concentrate Market through MarketsandResearch.biz Studies current market conditions and projects industry growth from 2021 to 2027. This research examines past growth trends, current growth factors, and anticipated future developments. The key outlook for the Alfalfa Concentrate industry is assessed and the components that stimulate and will drive the development of the industry […]]]>

the Global Alfalfa Concentrate Market through MarketsandResearch.biz Studies current market conditions and projects industry growth from 2021 to 2027. This research examines past growth trends, current growth factors, and anticipated future developments. The key outlook for the Alfalfa Concentrate industry is assessed and the components that stimulate and will drive the development of the industry are highlighted. Past growth trends, current growth factors, and anticipated future developments are all examined in this study.

Market position, profit margins, future progress, economic variables, opportunities, difficulties, dangers and barriers to entry are all factors in the Alfalfa Concentrate business. When analyzing the manufacturing process, the distribution of production plants, capacities, raw material supply, R&D status, technology source and commercial production are all taken into account. This section provides an overview of the alfalfa concentrate industry in general.

DOWNLOAD A SAMPLE FREE REPORT: https://www.marketsandresearch.biz/sample-request/242793

Their organizational structure as well as their production technique are studied. This data is analyzed using SWOT analysis and other methods to offer an informed opinion on the state of the market, encourage the adoption of an ideal development plan for any organization or provide insight into the market. future state of the alfalfa concentrate industry.

The industry is divided into divisions to adapt to different market characteristics.

  • Animal feed industry
  • Food industry
  • Medicines and health products
  • Others

Every major player in the business is investigated, including

  • Desialis
  • Phytochem Jiaherb Shaanxi
  • Naturaline
  • Nanjing Zhi Bai Cui Biology Technology
  • Changsha Active Ingredient Group
  • Biotanical extract 3W
  • Refine biology
  • Hunan NutraMax
  • Acetar Bio-Tech
  • Carli Group

It focuses on different market segments. Alfalfa concentrate

  • Alfalfa concentrate powder
  • Alfalfa concentrate pellets
  • Others

The industry is divided into distinct sectors.

  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, United Kingdom, Russia, Italy and rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
  • South America (Brazil, Argentina, Colombia and the rest of South America)
  • Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, South Africa and Rest of Middle East and Africa)

ACCESS TO THE FULL REPORT: https://www.marketsandresearch.biz/report/242793/global-alfalfa-concentrate-market-2021-by-manufacturers-regions-type-and-application-forecast-to-2026

This is divided into several sections. This research assesses the market potential of each geographic area in terms of growth rate, macroeconomic factors and consumer buying habits. The research provides companies and other customers interested in entering the global or regional market with the most recent comparison statistics as well as practical advice. Market position, profit margins, future developments, economics, opportunities, obstacles, risks, and entry barriers are all taken into account in the Lucerne Concentrate industry.

Customization of the report:

This report can be customized to meet customer requirements. Please connect with our sales team ([email protected]), which will make sure you get a report that’s right for you. You can also contact our leaders at + 1-201-465-4211 to share your research needs.

Contact us
Brand Pierre
Head of Business Development
Call: + 1-201-465-4211
E-mail: [email protected]
The Web: www.marketsandresearch.biz

Read more:

Global Can Sleeve Market 2021 Industry Key Player, Trends and Segmented Data, Demand and Forecast by 2027

Global Oven Toaster Market: Demand Study and Forecast to 2021-2027

Global Structural Engine Oil Sump Market 2021 Market Opportunity Assessment, Business Opportunities, Major Industry Players, Trend and Growth Till 2027

Chart 2021 Global Paper Making Machinery Market – Industry Report Analysis, Geographic Scope, Growth Tactics, and Forecast by 2027

Global Heat Pump Chiller Market 2021 Opportunities, Challenges, Key Players, Trend and Forecast by 2027

Global Luxury Living Room Furniture Market 2021 – Industry Parameters, Upcoming Trends, Key Business Priorities and Report Targets by 2027

Global Parenteral Drug Glass Packaging Market Business Overview 2021, Size Estimation, Research Strategies with Share Analysis, and Forecast to 2027

Global Online Car Rental Platforms Market 2021 with Impact of COVID-19 Outbreak, SWOT Study, Steady Growth and Forecast 2027

Global Positive Train Control Market 2021-2027 Research Study Provides Projections of COVID-19 Pandemic in New Report

Global Silicon Drift Detection Equipment Market 2021 Technological Innovations, In-Depth Qualitative Assessment, and Industry Value Chain to 2027

Global Discrete Semiconductor Device Testing Systems Market 2021 Industry Analysis by Manufacturers, End User, Type, Application, Regions, and Forecast to 2027

Global PCI Motion Control Cards Market 2021 (COVID-19 UPDATE) Future challenges, growth statistics and forecast till 2027

Global Cold Rolled Precision Stainless Steel Strip Market Size, Share, Analysis, Demand, Growth Driver, and Industry Segments by 2027

Global Lithium-Bis (Fluorosulfonyl) Imide (LiFSI) Market Growth Rate 2021, Key Manufacturer Profiles, Applications, Gross Margin and Market Share 2027

Global Asset Tokenization Platforms Market Business Outlook 2021 with COVID-19 Scenario to 2027

Global Paid Search Intelligence Software Market Report 2021 Major Key Players, Exploring Revenue and Sales Volume Forecast by 2027

Global Connected Worker Platforms Applications Market 2021, SWOT Analysis, Remarkable Growth and Competitive Landscape by 2027

Global Portable Vacuum Systems Market 2021 Growth Overview, Product Profitability and 2027 Forecast

Global Home Use Water Flossers Market Report 2021 to 2027 – Key Companies Impacting COVID-19 on the Industry

Global Flexible Colonoscopes Market 2021-2027 Research Report Segment Outlook, Growth Potentials, and Analysis of Global COVID-19 Outbreak


Source link

]]>
Retired MSU biology professor Dr David Magrane dies https://e-jemed.org/retired-msu-biology-professor-dr-david-magrane-dies/ Tue, 04 Jan 2022 15:09:29 +0000 https://e-jemed.org/retired-msu-biology-professor-dr-david-magrane-dies/ News January 4, 2022 Morehead State University mourns the death of retired biology professor Dr David Magrane, who died on Friday, December 31 in Lexington at the age of 79. Born January 6, 1942 in Ottumwa, Iowa, to the late George and Pauline Magrane, he was married to Mary Magrane. Magrane started his career at […]]]>

News


Morehead State University mourns the death of retired biology professor Dr David Magrane, who died on Friday, December 31 in Lexington at the age of 79.

Born January 6, 1942 in Ottumwa, Iowa, to the late George and Pauline Magrane, he was married to Mary Magrane.

Magrane started his career at MSU in 1976 as an assistant professor. He was named Outstanding Professor at MSU in 1998 and was nominated for the Carnegie Outstanding National Teacher Award in 2000. In the same year he was appointed Chairman of the Department of Biological and Environmental Sciences at MSU, a post he held. held until his retirement in 2007. In 2008, MSU honored Magrane by naming the University’s molecular biology laboratory in his honor. The name of the lab has been championed by colleagues and former students who raised funds to name the lab.

In addition to his wife, he is survived by four children, Joe (Renee) Magrane of Tampa, Florida; Jennifer Boatwright of Lexington; Joanie (David) Blevins from Flat Rock, Michigan; and Julie (Drew) Muntz from Richmond. He is also survived by his grandchildren, a brother and several nieces and nephews.

A gathering of family and friends will be held from 3 p.m. to 5 p.m. on Tuesday, January 4, 2022, at Family Worship Center, 6020 Tates Creek Rd, Lexington, followed by service at 5 p.m.


Source link

]]>
Israeli startup uses space biology to better treat cancer https://e-jemed.org/israeli-startup-uses-space-biology-to-better-treat-cancer/ Sun, 02 Jan 2022 13:56:42 +0000 https://e-jemed.org/israeli-startup-uses-space-biology-to-better-treat-cancer/ While most biotech companies focus on the molecular biology aspect and study the composition and structure of molecules in cells, an Israeli startup claims to have found the solution by combining artificial intelligence, big data and computational biology . Nucleai is interested in the spatial aspect, or the way in which molecules are arranged inside […]]]>
While most biotech companies focus on the molecular biology aspect and study the composition and structure of molecules in cells, an Israeli startup claims to have found the solution by combining artificial intelligence, big data and computational biology . Nucleai is interested in the spatial aspect, or the way in which molecules are arranged inside human cell tissue in a 2D context. Four years ago, Avi Veidman, co-founder and CEO, started the company, alongside COO Eliron Amir and Lotan Chorev after the trio served together in the Israeli intelligence service. Nucleai’s software uses computer vision and machine learning algorithms to predict the progression of cancerous tumors as well as predict the responses of each patient’s immune system to find the most effective treatment.

From satellites to cancer cells

Veidman shared the story of Nucleai’s birth. While in the intelligence corps, he worked in a defense department that used satellites to monitor enemy infiltrations across Israel’s borders. “I went from looking for bad guys in satellite images to looking for bad guys in cancer cells,” he joked. And around the same time he was leaving defense, his father needed an urgent biopsy. When Veidman spoke with medical professionals, he was surprised and shocked to learn that it could take a month for these results to be obtained. “I was wondering why we couldn’t just create an algorithm and use a computer to find these cells,” he told CTech in an interview. Currently, in biopsies, doctors take a very small slice of tissue and send it to a pathologist for analysis, who uses a microscope to locate cancer cells. This process, relayed Veidman, is totally outdated and was a market in need of disruption. And after developing software to automatically analyze satellite images, he wondered why the trio couldn’t do the same with cancer cells. “We wanted to create a startup, but one that was working on something noble,” he said. And that’s how Nucleai was born.

The Nucleai team. Photo: David Grob

Although science has advanced since the sequencing of the human genome, there is still a fundamental lack of understanding why some patients respond to various drugs and others do not. “On average, only one in three patients will respond to new cancer drugs,” added Veidman. Nucleai’s platform, he explained, uses spatial biology methods as well as genomic data to find where cancer cells are in human cells in order to target them more precisely. Simultaneously, Nucleai is working with several large pharmaceutical companies to use its platform and thus develop better drugs. “We recommend that cancer patients enroll in clinical trials, and as they progress we can help pharmaceutical companies better develop these drugs, using screening criteria and companion diagnostics. “, did he declare. Doctors can then prescribe drugs that are best suited to each patient using data obtained from the Nucleai platform.

Pioneering biology

Nucleai’s algorithms predict the progression of cancerous tumors by analyzing the stroma (or tissue) and examining where cancer cells are located or scattered within the cell, and how they interact with other healthy human cells. Specifically, it examines and analyzes immune cells (T cells) and cancer cells and their interactions, plots them later, and provides a detailed worksheet of each part of the stroma in an organized manner, listing all the categories and characteristics of all. cells in a certain area. Nucleai trained his algorithm using earlier data sets he obtained from various hospitals. Recently, it signed strategic partnerships to share even more data with medical centers in the United States and Israel, including Sheba, Rambam and Kaplan Medical Centers, Clalit (Israel’s largest HMO), Jefferson Medical Center in West Virginia and the University of Pennsylvania. . This will allow the company to access an even greater amount of pathology slides and clinical data that can be used to refine the algorithms.

“Our platform finds a ‘fingerprint’ that describes a certain population of people who would respond to a drug by comparing facts as well as listing data on those who don’t. Precision medicine can help identify certain factors that can help treat people individually, while traditional medicine cannot. Our platform really adds value to personalized treatment, ”he said. And this space biology transcriptomics method was named New Age and New Revolution Biotechnology Method of the Year by the prestigious scientific journal Nature in 2020, making it a promising field for biotechnology companies in the world. which to innovate. underutilized, and we’re bringing it to the forefront of precision medicine through our platform. We enable pharmaceutical companies to develop a higher likelihood of success and help patients get the right treatment at the right time.

Cancer cells (stained dark purple) are visible on this slide using the Nucleai platform.  Photo: Nucléai Cancer cells (stained dark purple) are visible on this slide using the Nucleai platform. Photo: Nucléai

The platform works to analyze many types of cancer, including lung, gastrointestinal, cervical, breast, prostate, urethra, and skin cancers. Part of what makes the platform so pioneering is the fact that it works directly with pharmaceutical companies in their early stages of development and supports them later when they conduct clinical trials before attempting to obtain the FDA approval. “They show us which patients have responded to a new drug and which have not. They then upload those slides to our platform, which further helps ‘train’ our algorithm, ”he said. So far, Nucleai has also partnered with 10 pharmaceutical companies such as Merck & Co., Inc. and Debiopharm Group. When the drug becomes available and used in hospitals, doctors can check whether it is suitable for a certain patient and upload their results to the Nucleai platform. In this way, there is a constant flow of data between drug research and development and the actual treatment of patients in real time, he noted.

Leading investors

So far, the company has raised $ 15 million in two rounds of funding, including via seed and Series A from leading investors, Debiopharm, a Swiss pharmaceutical group, and Israeli venture capital funds. , Vertex Ventures, Grove Ventures and the Chinese company Fusun RZ. Capital city. Nucleai is also on the cusp of concluding a Series B round with many high profile undisclosed investors in the United States. Based in Tel Aviv, the company also has a commercial arm in Chicago and plans to open branches in Boston and the Bay Area. Its multidisciplinary teams include artificial intelligence specialists, software engineers, computer biologists, as well as salespeople and salespeople. As for gender diversity, Veidman noted that the company employs several women in its technical teams. “Diversity brings a lot of value to our business, especially having different opinions, and really enriches our knowledge and makes us much better and stronger as a business. “

And the uniqueness of this technology can be particularly applied to Israel, which has a centralized healthcare system with a long history of electronic medical records, allowing easier access for companies such as Nucleai. “We have access to unique and huge amounts of data that allow us to develop a more generalized model,” he said. Currently, Nucleai is working with a few undisclosed pharmaceutical companies on various Phase 2 and 3 clinical trials for the treatment of non-small cell lung, breast and cervical cancers. “At the end of the day, having these kinds of tools within our health system will allow us to find the right treatments for patients and save lives,” he reiterated.


Source link

]]>
Newfoundland biologist says bird flu in St. John’s is ‘of great concern’ for birds, not humans https://e-jemed.org/newfoundland-biologist-says-bird-flu-in-st-johns-is-of-great-concern-for-birds-not-humans/ Fri, 31 Dec 2021 20:51:36 +0000 https://e-jemed.org/newfoundland-biologist-says-bird-flu-in-st-johns-is-of-great-concern-for-birds-not-humans/ ST. JOHN’S, NL – A biologist from Newfoundland and Labrador says the discovery of highly pathogenic avian influenza in birds in St. John’s is “of great concern” to bird populations, but probably not to humans. Memorial University professor Andrew Lang said in an interview on Friday that the flu could be devastating to North American […]]]>

ST. JOHN’S, NL – A biologist from Newfoundland and Labrador says the discovery of highly pathogenic avian influenza in birds in St. John’s is “of great concern” to bird populations, but probably not to humans.

Memorial University professor Andrew Lang said in an interview on Friday that the flu could be devastating to North American wild bird populations if it manages to spread beyond the island of Earth. -New.

The city of St. John’s said in a statement Friday that the flu was found in local wild birds and that authorities have asked residents not to feed, handle or touch any birds, including gulls, ducks. and pigeons.

Environment Canada wildlife scientist Alan Hanson said in an interview on Friday that the flu was found in a black-backed gull that was found in a pond in St. John’s on November 26.

The news comes just days after an outbreak of H5N1 avian influenza was reported at an “show farm” on Newfoundland’s Avalon Peninsula, which killed 360 of the facility’s 419 birds.

Lang says there is “little to no evidence” that the strain poses a risk to humans, noting that it has manifested itself in several other parts of the world, such as Israel, where an outbreak has recently killed more people. 5,000 migrating cranes.

Lang said the current strain is particularly well suited for spreading among wild birds, as it kills many but leaves some alive. These infected birds can then spread the virus.

He said it is difficult to predict what will happen in Newfoundland.

“Best case scenario? Maybe he never leaves the island,” he said. “Maybe it’ll just go away; maybe we’ll be lucky.

As for the infected gull, Hanson said it was collected from Mundy Pond in the western part of the capital and presented to wildlife officials because it was behaving strangely. The bird died about 24 hours after its introduction, he said.

This report by The Canadian Press was first published on December 31, 2021.


Source link

]]>
Assistant / Associate / Full Professor in Structural Biology, Electron Cryo-microscopy 2022 job with KING ABDULLAH UNIVERSITY OF SCIENCE & TECHNOLOGY https://e-jemed.org/assistant-associate-full-professor-in-structural-biology-electron-cryo-microscopy-2022-job-with-king-abdullah-university-of-science-technology/ Wed, 29 Dec 2021 23:20:37 +0000 https://e-jemed.org/assistant-associate-full-professor-in-structural-biology-electron-cryo-microscopy-2022-job-with-king-abdullah-university-of-science-technology/ King Abdullah University of Science and Technology: Faculty positions: Division of Biological and Environmental Sciences and Engineering (faculty) Site King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia The description As part of a major initiative to strengthen research in structural biology and advanced imaging, the Biosciences Program of the Biological and Environmental […]]]>

King Abdullah University of Science and Technology: Faculty positions: Division of Biological and Environmental Sciences and Engineering (faculty)

Site

King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia

The description

As part of a major initiative to strengthen research in structural biology and advanced imaging, the Biosciences Program of the Biological and Environmental Sciences and Engineering Division (BESE) of KAUST is looking for structural biologists with strong expertise in cryo- electron microscopy (cryo-EM). Applications for faculty positions at all ranks (Assistant, Associate or Full Professor) are invited by highly competitive applicants with strong technical background in cryo-EM, who are eager to pursue impactful research to advance innovative technology. and / or fundamental questions in bio, marine or plant sciences. Successful applicants must have a doctorate. in biological sciences or related fields, as well as solid publication experience in high-level sites in their respective fields.

KAUST’s Biosciences program offers a unique combination of an intellectually stimulating environment and access to world-class laboratories, instruments and generous funding programs. KAUST Provides Outstanding Structural Biology Research Facilities, Including a Titan KRIOS G4 [with cold FEG illumination, Ceta D camera, Selectris X and Falcon 4 and phase plate and access to powerful GPU computer clusters], Titan KRIOS G1 [with phase plates, Quantum GIF Gatan filter (model 968), K2 Summit direct detector and access to powerful GPU computer clusters], NMR spectrometers (600, 700, 800 and 950 MHz) and an internal X-ray source. KAUST’s facilities also include state-of-the-art genomics, proteomics, imaging and characterization, extreme computing and informatics laboratories, as well as an animal resources laboratory. The structure and organization of KAUST are particularly suited to out-of-the-box interdisciplinary collaborative research and offer strong support to translate research into impactful innovations.

The position will remain open until it is filled.

About KAUST

KAUST is an international graduate research university dedicated to the advancement of science and technology through interdisciplinary research, education and innovation. KAUST attracts the best international professors, scientists, engineers and students to conduct curiosity-driven, goal-oriented research to address the world’s most pressing science and technology challenges. Located in Saudi Arabia, on the eastern shores of the Red Sea, KAUST offers an award-winning campus for living, working, studying and playing, and offers superb research facilities, with guaranteed core research funding, infrastructure support , entrepreneurship opportunities and international competitiveness. wages. For more information on KAUST, please visit http://www.kaust.edu.sa. More information on the BESE division and the Biosciences program is available at http://bese.kaust.edu.sa.

Application Instructions

To avoid any delay in reviewing your application, you will need to upload the following documents:

  • A cover letter presenting your application and explicitly indicating both the position and the rank. The rank should be consistent with the candidate’s experience.
  • Up-to-date curriculum vitae, including full list of publications.
  • Declaration of research interests (5 pages maximum).
  • Statement of teaching interests (2 pages maximum) including teaching philosophy and an outline of 1 to 2 planned higher education courses.
  • Names and contact details of at least 4 references. Arbitrators must occupy positions in university or industrial research laboratories. In the case of applications from associate and full professors, the references must be of a rank higher or equivalent to that of the candidate.
  • Copies of the most relevant publications (maximum of five).


Source link

]]>
Biological E aims to produce 100 million doses / month of Corbevax from February 2022 https://e-jemed.org/biological-e-aims-to-produce-100-million-doses-month-of-corbevax-from-february-2022/ Tue, 28 Dec 2021 10:51:30 +0000 https://e-jemed.org/biological-e-aims-to-produce-100-million-doses-month-of-corbevax-from-february-2022/ Corbevax, the first protein subunit vaccine developed in India against the virus, received approval today from the Comptroller General of Medicines of India (DGCI), he said. Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 Corbevax vaccine per month, anticipating more than 100 million doses per month […]]]>

Corbevax, the first protein subunit vaccine developed in India against the virus, received approval today from the Comptroller General of Medicines of India (DGCI), he said.

Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 Corbevax vaccine per month, anticipating more than 100 million doses per month from February 2022, which will allow the company based in the city to deliver 300 million doses as promised to the Center, BE said on Tuesday.

Corbevax, the first protein subunit vaccine developed in India against the virus, received approval today from the Comptroller General of Medicines of India (DGCI), he said.

According to a press release issued soon by the vaccine maker, the company plans to deliver more than a billion additional doses worldwide.

Biological E. Limited plans to complete production at a rate of 75 million doses per month, anticipating more than 100 million doses per month from February 2022. These capacities will allow the Hyderabad-based company to deliver 300 million doses as promised to the government of India, ”he said.

The vaccine was developed by Biological E. Limited in collaboration with the Texas Children’s Hospital Center for Vaccine Development (Texas Children’s CVD) and Baylor College of Medicine (Baylor) in Houston, Texas.

Mahima Datla, Managing Director of BE limited, said: “Over the years, we have worked to make quality vaccines and pharmaceuticals accessible to families around the world. In this context, we decided to develop an affordable and effective COVID-19 vaccine. It has now become a reality.

Corbevax has completed two Phase III clinical trials involving more than 3,000 subjects aged 18 to 80 at 33 study sites across India. The vaccine has been shown to be safe, well tolerated and immunogenic, the company said.

In the pivotal phase III study conducted with an endpoint of immunogenic superiority, Corbevax demonstrated a superior immune response compared to the Covishield vaccine when evaluated for geometric mean titers (GMT) of neutralizing antibodies ( nAb) against the Ancestral-Wuhan strain and the globally dominant Delta variant, the statement said.

“Our scientists at Texas Children’s Hospital and Baylor College of Medicine are delighted to assist in the development of this vaccine, possibly the first covid vaccine specifically designed for global health,” Peter Hotez, Professor and Dean of the National Baylor School of Tropical Medicine. and co-director of the Texas Children’s Hospital Center for Vaccine Development said.

Financial Express is now on Telegram. Click here to join our channel and stay up to date with the latest news and updates from Biz.


Source link

]]>
Research by team of American and Indian scientists suggests cancer therapy without chemo https://e-jemed.org/research-by-team-of-american-and-indian-scientists-suggests-cancer-therapy-without-chemo/ Sun, 26 Dec 2021 17:48:39 +0000 https://e-jemed.org/research-by-team-of-american-and-indian-scientists-suggests-cancer-therapy-without-chemo/ A team of American and Indian scientists, backed by their research, hinted at a new effective cancer treatment process without chemotherapy or radiation therapy known to cause side effects such as fatigue, nausea, hair loss, weight loss, pain. , diarrhea, gastrointestinal problem, immunosuppression, in addition to sore mouth and throat in most cancer patients. The […]]]>

A team of American and Indian scientists, backed by their research, hinted at a new effective cancer treatment process without chemotherapy or radiation therapy known to cause side effects such as fatigue, nausea, hair loss, weight loss, pain. , diarrhea, gastrointestinal problem, immunosuppression, in addition to sore mouth and throat in most cancer patients.

The results of this team of 10 scientists working in the field of cancer at the Cleveland Clinic in the United States led by professor of cancer biology Yong Li and assistant professor of biochemistry at Allahabad University (AU) Munish Pandey were recently published in the prestigious international journal Oncogene of Nature Publishing Group.

After successful experiments in mice, efforts are now being stepped up to do the same for human trials, scientists say. “The study may provide relief to cancer patients who undergo chemotherapy. Chemotherapy uses radiation and other drugs that have many side effects and cause an immune system response that causes severe pain and allergic reactions. Our team had previously developed knockout mice (a lab mouse in which one or more genes were turned off or ‘knocked out’ by genetic engineering) for miR-21 and the same has been published in the journal PNAS, ”a Pandey said.

Knockout mice are used to study what happens in an organism when a particular gene is missing. MicroRNA-21 (small non-coding RNA) is one of the most abundant microRNAs in mammalian cells that regulate apoptosis (programmed cell death) and oncogenic effects.

He said his team was on the verge of finding an alternative to chemotherapy and cancer treatment drugs that damage normal cells as well as cancer cells during cancer treatment. In this successful experiment at the Cleveland Clinic in the United States, the team, while experimenting on mice, injected its antisense (non-coding DNA strand of a gene) into mice to render miR-21 ineffective. .

After that, it was found that the tumor formed in the body of mice gradually became smaller. Some tumors have even disappeared. This experiment lasted a year in the United States. However, it has yet to gain approval for a human trial.

During the research, the team also found that microRNA, i.e. miR-21, was significantly expressed in most types of cancer. “It makes cancer cells more efficient in the presence of miR-21,” Pandey said. “The group is also working on other mechanisms of programmed cell death, microRNAs and chimeric antigen T cell therapy (CAR-T) to combat carcinogenicity in mice,” he added.


Source link

]]>
Biology is unlikely to cause ethnic differences in COVID-19 risk for healthcare workers https://e-jemed.org/biology-is-unlikely-to-cause-ethnic-differences-in-covid-19-risk-for-healthcare-workers/ Wed, 22 Dec 2021 20:44:55 +0000 https://e-jemed.org/biology-is-unlikely-to-cause-ethnic-differences-in-covid-19-risk-for-healthcare-workers/ Credit: Unsplash / CC0 Public domain Differences in risk of COVID-19 infection between ethnic minority healthcare workers and their white colleagues are likely due to domestic and work factors rather than biology, according to the largest and most recent study detailed on the subject, co-edited by researchers at University College London (UCL). Previous research has […]]]>

Credit: Unsplash / CC0 Public domain

Differences in risk of COVID-19 infection between ethnic minority healthcare workers and their white colleagues are likely due to domestic and work factors rather than biology, according to the largest and most recent study detailed on the subject, co-edited by researchers at University College London (UCL).

Previous research has shown that healthcare workers from ethnic minority groups are at a disproportionately higher risk of contracting COVID-19 than their white colleagues. Baseline data from the UK-REACH study confirms this. Of 10,772 healthcare workers participating in the study, black healthcare workers were significantly more likely to have evidence of COVID-19 infection than white healthcare workers.

However, after work-related factors, such as position and place of work, the number of COVID-19 patients they have treated, and lifestyle factors, such as living with other healthcare workers and age are taken into account, this difference in risk is no longer seen. This implies that these home and lifestyle factors, rather than anything innate / biological, are responsible for the disproportionate risk of COVID-19 among ethnic minority healthcare workers.

The study, posted on the MedRxiv pre-print server and carried out with the University of Leicester and the University of Nottingham found that a higher risk of COVID-19 infection among healthcare workers was associated nursing or midwifery work, exposure to increasing numbers of COVID-19 patients, lack of access to PPE, living with another key worker, and working in hospitals or ambulances.

Additionally, those working in Scotland and the South West of England have a lower risk of infection than healthcare workers in the West Midlands, as are those working in intensive care units (ICUs). .

Co-author Professor Katherine Woolf (UCL Medical School) said: “There is concern that black healthcare workers are at greater risk of reporting COVID-19 infection. Our study suggests that this higher risk was due to the fact that black healthcare workers were more exposed to the virus at work and / or outside of work, rather than because of inherent biological or genetic factors. reduce their chances of catching COVID-19, in particular by being supported to take booster vaccines. This is especially important now, as the Omicron variant of the virus is much easier to catch than previous variants. “

Dr Manish Pareek, associate professor of infectious diseases at the Biomedical Research Center at the National Institute for Health Research (NIHR) Leicester and lead investigator of the UK-REACH study, said: ‘Our study shows the importance of occupational risk and life at home. For example, it shows a strong association between the number of COVID-19 patients followed by a healthcare professional and the healthcare professional’s risk of infection. This is not in all situations: times their risk of infection was higher than those who had not reported access problems.

“On the other hand, those who worked in intensive care units, where long-sleeved gowns and respiratory masks are recommended at all times, were at less risk than those who did not work in this environment. This supports the idea of ​​improving PPE standards for all healthcare workers. Managing COVID-19 patients, regardless of location or type of procedure performed, can have a beneficial impact in reducing infection rates among staff. “

Dr Christopher Martin, academic researcher in infectious diseases at the University Hospitals of Leicester NHS Trust and first author of the study, said: “We have identified the main risk factors associated with COVID-19 infection among role workers and living with other key workers.Healthcare workers from black ethnic groups in our study were younger, more likely to work in environments such as inpatient care, more likely to see a number more COVID-19 patients and less likely to report having access to appropriate PPE at all times than their white colleagues. They were also more likely to live with other key workers and in more disadvantaged areas.

“All of these factors increase their risk of COVID-19. However, once these factors are taken into account, the difference in risk of infection between black and white healthcare workers was negligible, suggesting that the differences in life occupational and family health workers from ethnic minorities – some of which are linked to inequalities more generally – lead to different infection rates. These important findings should inform policies, including targeted vaccination strategies and health assessments. risks aimed at protecting healthcare workers during future waves of the COVID-19 pandemic. ”

The results are particularly timely, given the emergence of the highly infectious Omicron variant of the coronavirus, which may be better able to evade vaccination-induced protection against infection, which could lead to more numbers. high number of healthcare workers contracting the disease.

The authors acknowledge that the study has limitations, such as the potential for self-selection bias, meaning that healthcare workers might be more inclined to complete the survey if they felt they were running greater risk of infection, for example. However, the study is the largest and most detailed to date, focusing specifically on the risks to healthcare workers. The sample of 10,772 people is broadly representative of the NHS workforce, albeit with fewer support staff, and the infection rates reported in the study are consistent with those reported in other studies British.

The results were posted on MedRxiv as a pre-print, meaning the results have yet to be peer reviewed.


Long-term COVID impact on ethnic minority healthcare workers investigated


More information:
Christopher A. Martin et al, Predictors of SARS-CoV-2 infection in a multiethnic cohort of UK healthcare workers: a nationwide prospective cohort study (UK-REACH), ( 2021). DOI: 10.1101 / 2021.12.16.21267934

Provided by University College London

Quote: Biology is unlikely to cause ethnic differences in COVID-19 risk for healthcare workers (2021, December 22) Retrieved December 22, 2021 from https://medicalxpress.com/news/2021-12 -biology-ethnic-differences-covid-healthcare. html

This document is subject to copyright. Other than fair use for private study or research purposes, no part may be reproduced without written permission. The content is provided for information only.


Source link

]]>
SynBioBeta LIVE conference postponed from April 12 to 14, 2022 https://e-jemed.org/synbiobeta-live-conference-postponed-from-april-12-to-14-2022/ Tue, 21 Dec 2021 07:37:48 +0000 https://e-jemed.org/synbiobeta-live-conference-postponed-from-april-12-to-14-2022/ SynBioBeta was more than excited to bring together the bioeconomy community with investors, bio-curious, the press and our Race Against the Clock students and start-ups from January 25-27 … our aim being to celebrate the incredible progress that we have accomplished. made over the past two years and vision for the revolutionary tools, technologies and […]]]>

SynBioBeta was more than excited to bring together the bioeconomy community with investors, bio-curious, the press and our Race Against the Clock students and start-ups from January 25-27 … our aim being to celebrate the incredible progress that we have accomplished. made over the past two years and vision for the revolutionary tools, technologies and products our community relies on to make the planet a better place!

Unfortunately, the new Omicron COVID variant made the January dates too risky for a live event; We have therefore moved the dates for the in-person conference from Tuesday April 12 to Thursday April 14 2022, still at the Oakland Marriott City Center. (See FAQ list below for more details)

We apologize for any issues this turn of events may cause, but you agree, safety must be our top priority.

Please know that our SynBioBeta team are committed to serving each of you well and look forward to seeing you in person on our new dates, April 12-14, 2022 at the Oakland Marriott City Center.

Truly,
The Built With Biology team


SYNBIOBETA PIVOT AT APRIL 12-14 FAQ

TICKET HOLDERS / EXHIBITORS

Your conference tickets will automatically be carried over to the new dates, so no further action is necessary on your part.

If you have a schedule conflict with the new dates, please email Anissa Cooke (anissa.cooke@synbiobeta.com)

HOTEL RESERVATIONS

Any previous hotel reservations will be automatically canceled this week (free of charge).

A new block of our discounted rooms at the Oakland Marriott City Center will be provided to us in early January. We negotiated the same great price with the hotel and received a larger block of rooms for April, so more conference attendees could stay on site. We will send you the new hotel reservation link in early January.

HAPPY HOLIDAYS

We would like to end by wishing each of you a happy, healthy and fun holiday season! We’ve had a few roaring years, but we’ve made it this far and have an incredibly bright future!

Synbiobeta Built with Biology World Conference:
Oakland, California. From April 12 to 14, 2022!


Source link

]]>